Skip to main content

Table 2 Baseline, final, and change values for the included studies

From: Effect of metformin on left ventricular mass and functional parameters in non-diabetic patients: a meta-analysis of randomized clinical trials

Author

LVMI (g/m2)

LVEF (%)

NT-ProBNP

E/e′ ratio

E

C

E

C

E

C

E

C

Ali [32]

B: 89 (75, 105)

B: 85 (73, 101)

B: 52 (45, 59)

B: 52 (46, 57)

B: 79.5 (42, 179)

B: 68 (37, 177)

B;7.8 (6.7, 9.6)

B:7.1 (5.9, 9.7)

F4: 88.4 (75.7, 100.9)

F4: 85.7 (73.6, 97.0)

F4: 55 (48, 60)

F4: 58 (53, 63)

F4:7.6 (6.4, 9)

F4:7.5 (6.2, 8.7)

4: − 2.7 (− 16.0, 6.9)

4: 0.6 (− 13.5, 9.1)

4: 3.2 (− 2.9, 7.6)

4: 3.7 (0.3, 10.6)

4: − 0.1 (− 1.3, 1.0)

4:0.2 (− 1.3, 1.9)

Gupta [33]

  

B: 46.0 (36.0–56.0)

B: 43.0 (33.0–50.0)

B: 996 (333–1798)

B: 903 (464–1378)

  

F12: 51.0 (42.0–61.0)

F12: 45.0 (35.0–52.0)

F12: 517 (246–1219)

F12: 701 (476–1157)

: NR

: NR

: NR

: NR

Ladeiras-Lopes [15]

B: 88.7 ± 23.4

B: 84.6 ± 18.9

B: 58.4 ± 3.8

B: 60.1 ± 3.6

B: 52 (29–78)

B; 42 (14–52)

B: 9.3 ± 1.9

B: 8.6 ± 1.9

MITT 6: 4.50 (14.81)

MITT 6: 2.57 (15.43)

MITT 6: 7.38 (34.02)

MITT 6: 6.43 ± 22.4

MITT 6: − 0.69 ± 1.28

MITT 6: 0.28 ± 1.10

12: − 4.12 (17.06)

12: − 0.20 (16.33)

12: 3.25 (19.49)

12: 3.32 ± 12.38

12: − 0.31 ± 1.60

12: 0.12 ± 1.28

24: − 0.29 (15.30)

24: 3.45 (14.75)

24: 9.71 (31.83)

24:1.35 ± 32.86

24: − 0.57 ± 1.61

24: 0.02 ± 1.54

Larsen [16]

B: 98 ± 25

B: 92 ± 25

B: 36 ± 9

B: 39 ± 6

B: 353 [222–896]

B: 364 [94–744]

B: 12 [11,12,13,14]

B: 11 [9,10,11,12,13,14]

F3: 97 ± 22

F3: 94 ± 29

F3: 37 ± 10

F3: 38 ± 11

F3: 442 [194–1190]

F3:357 [103–562]

F3: 11 [9,10,11,12,13,14]

F3: 11 [9,10,11,12,13,14,15]

3: NR

3: NR

3: NR

3: NR

3: NR

3: NR

3: NR

3: NR

Mohan [14]

B; 48.7 ± 6.5

B; 46.0 ± 9.3

12 (MITT): − 3.58 ± 7.9

12 (MITT): − 3.53 ± 6.6

B: 957.8 ± 1029

B: 796.5 ± 1247

  

12 (MITT): − 2.71 ± 2.31

12 (MITT): − 1.34 ± 2.66

12 (PP): − 4.11 ± 8.4

12 (PP): − 3.90 ± 6.81

12 (MITT):309 ± 1390

12 (MITT):99 ± 475

12 (PP): − 3.12 ± 1.95

12 (PP): − 1.29 ± 2.67

12 (PP): 376 ± 1479

12 (PP): 70 ± 458

Sardu [34]

B: 94.11 ± 22.13

B: 93.54 ± 21.88

B: 52 ± 7

B:52 ± 7

    

F; 56.13 ± 16.18

F; 79.81 ± 16.83

F12: 57 ± 5

F12: 54 ± 8

12: NA

12: NA

Stakos [35]

B: 123 ± 23.6

B: 127 ± 29.2

      

12: − 8.1 ± 3.4

12: − 2.9 ± 2.9

24: − 16.8 ± 7.0

24: − 0.2 ± 4.1

Velázquez [18]

B: 99.7 ± 20

B: 96 ± 26

B: 71 ± 55

B: 71 ± 40

  

B: 9.5 ± 2.5

B: 10.6 ± 2.3

F6: 89 ± 18

F6: 98 ± 23

F6: 73 ± 58

F6: 68 ± 29

F6: 9.59 ± 2.1

F6: 10.4 ± 1.5

6: NR

6: NR

6: NR

6: NR

6: NR

6: NR

Wong [17]

  

B: 34 ± 8

B: 30 ± 8

BNP

BNP

  

4: 0.35 + 5.50

4: − 1.10 + 4.20

B:131.7 ± 158.5

B: 187.1 ± 251.3

4: − 20.2 ± 78.7

4: 7.5 ± 131.2

  1. Data was presented as mean ± standard deviation or median [interquartile range]
  2. B: Baseline, F3: Final value at 3 months, F4: Final value at 4 months, F6: Final value at 6 months, F12: Final value at 12 months
  3. 3: Change at 3 months, 4: Change at 4 months, 6: Change at 6 months; 12: Change at 12 months, 24: Change at 24 months
  4. C: Control group; E: Experimental group
  5. MITT modified intention to treat, NR not reported, PP per protocol
  6. LVMI was indexed to height1.7